Producer
Gland Pharma Limited
Indian sterile injectables CDMO; majority owned by Fosun Pharma (China); received FDA ANDA approval for generic latanoprost ophthalmic solution December 2024.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Gland Pharma Limited supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Gland Pharma Limited makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Injectable Generics (US/EU ANDA Portfolio)
60%CDMO Services (Contract Manufacturing)
30%Fosun Pharma Context
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Origin2023
Gland Pharma Limited — the largest Indian sterile injectable CDMO by ANDA count — is majority-owned by Fosun Pharma (Shanghai, China; HKEX: 2196), making it the most significant case of Chinese majority control over a major Indian pharmaceutical manufacturer. Fosun Pharma acquired Gland in 2017 for approximately USD 1.09 billion in what was the largest Chinese acquisition of an Indian pharmaceutical company at the time. The ownership was largely unremarkable until 2020, when Indian and Chinese border forces clashed in the Galwan Valley, killing 20 Indian soldiers and triggering significant India-China tensions. India subsequently implemented stricter automatic foreign direct investment (FDI) approval requirements for Chinese-invested entities (mandatory government review versus automatic clearance). Gland's pre-existing Fosun ownership was grandfathered under prior FDI rules. The situation created an unusual dual supply chain concern: US pharmaceutical companies contracting with Gland for sterile manufacturing must evaluate whether a Chinese-majority-owned Indian CDMO represents a supply chain security risk, even as Gland remains operationally Indian-run and USFDA-qualified.
Gland Pharma Limited ↗Did you know2023
Gland Pharma's sterile injectable platform serves multiple critical care therapeutic areas simultaneously from the same Hyderabad GMP facilities: (1) Cancer chemotherapy — generic carboplatin, oxaliplatin, and other platinum-based oncology IV drugs; used in hospital oncology infusion centers; (2) Serious bacterial infections — generic vancomycin (MRSA treatment), meropenem (carbapenem antibiotic for multidrug-resistant Gram-negative infections), and piperacillin-tazobactam; hospital pharmacy critical medications; (3) Ophthalmic disease — generic latanoprost eye drops (FDA ANDA approval December 2024) for glaucoma; (4) Anticoagulation — injectable heparin and related generics. A shared set of Hyderabad aseptic fill-finish manufacturing assets simultaneously services ICU antibiotics, cancer chemotherapy, eye disease treatment, and blood clot prevention. A quality or supply disruption at Gland would cascade simultaneously into cancer care, infectious disease treatment, and preventive medicine — a CDMO concentration risk across multiple hospital critical care sectors under Chinese majority ownership.
Gland Pharma Limited ↗